Financial Performance - Generated $11.2 million in net sales, a 52% increase year-over-year, and a 22% sequential growth over Q1 2025[5] - Gross margins were 84% in Q2 2025, down from 88% in the same period of 2024, primarily due to lower manufacturing efficiency associated with newly launched products[5] - Operating losses were $7.3 million, improved from $8.2 million in Q2 2024, due to reduced R&D expenses[10] - Net loss attributable to common stockholders was $9.0 million, compared to $5.1 million for the same period in 2024[10] - Adjusted EBITDA losses were $5.3 million, an improvement from losses of $6.7 million for the same period in 2024[6] - Net loss available to common stockholders for Q2 2025 was $8,288 million, compared to a loss of $4,332 million in Q2 2024, reflecting a deterioration of 91%[18] - Adjusted EBITDA for Q2 2025 was $(5,275) million, an improvement from $(6,705) million in Q2 2024, indicating a reduction in losses by 21%[18] Expenses - Research and Development (R&D) expenses were approximately $3.9 million, a decrease from $4.7 million in the same quarter of the prior year[5] - Sales and Marketing (S&M) expenses increased to approximately $7.2 million from $6.0 million year-over-year, reflecting continued investment in commercial expansion[5] - Interest expense for Q2 2025 was $1,423 million, up from $877 million in Q2 2024, an increase of 62%[18] Guidance and Market Response - The company reaffirmed its full-year revenue growth guidance of at least 50%, driven by increased market penetration within liver-directed therapies[2] - The TriNav FLX product launch has received strong early market response, with sales surpassing internal projections[5] Assets and Liabilities - Total assets increased to $41,317 million as of June 30, 2025, up from $23,971 million at December 31, 2024, representing a growth of 72%[15] - Current assets rose to $38,084 million, compared to $20,669 million at the end of 2024, marking an increase of 84%[15] - Long-term debt increased to $32,274 million as of June 30, 2025, up from $22,084 million at December 31, 2024, a rise of 46%[15] - Total liabilities reached $60,740 million, compared to $49,865 million at the end of 2024, an increase of 22%[15] - Stockholders' deficit improved to $(19,423) million as of June 30, 2025, compared to $(25,894) million at December 31, 2024, a reduction of 25%[15] Cash and Inventory - As of June 30, 2025, cash and cash equivalents totaled $26.5 million, providing sufficient runway to reach positive adjusted EBITDA in the first half of 2026[10] - Cash and cash equivalents significantly increased to $26,490 million from $8,525 million, a growth of 210%[15] - Inventory decreased to $3,807 million from $4,048 million, a decline of 6%[15]
MEDTECH ACQUISIT(MTAC) - 2025 Q2 - Quarterly Results